Genica Genetic Tests for Cardiovascular Diseases
Cardiovascular

Genetic Tests for Cardiovascular Diseases

Early detection and diagnosis of cardiovascular disease can help prevent sudden cardiac death and improve the prognosis and treatment of affected patients. Genetic tests provide important diagnostic and prognostic information for myocardial infarction, deep vein thrombosis, arrhythmias, familial hypercholesterolemia, and others. Genetic testing can also identify asymptomatic and at-risk family members, allowing for early prevention or intervention to prevent illness or sudden death.

Our range of genetic tests for cardiovascular diseases is extensive and is continuously updated. Contact us if you cannot find a specific test you need.

Identification of 12 Genetic Variants

Predispositions to Cardiovascular Disease (CVD12)

The CVD12 genetic panel identifies 12 genetic variants associated with an increased risk of developing coronary artery disease, pulmonary thromboembolism, atherosclerosis, hypertension, and others. cardiovascular diseases. Risk factors include hypercoagulation, increased homocysteine, folate deficiency (Vitamin B9), increased fibrin formation, defects in the regulation and transport of cholesterol, decreased protection of cardiomyocytes.

Diagnostic Range: Genetic variants in the genes Factor V Leiden (FV), Factor V R2 (FVR2), Prothrombin (FII), Factor XIII (FXIII), β-Fibrinogen (FGB), Plasminogen Activator Inhibitor (PAI), Glycoprotein IIIa ), Methyltetrahydrofolate reductase (MTHFR 677C> T), Methyltetrahydrofolate reductase (MTHFR 1298A> C), Angiotensin converting enzyme (ACE), Apolipoprotein B (APOB), Apolipoprotein E (APOE) are analyzed

Diagnostic Method: PCR / Hybridization

Research Material: 6 ml venous blood / 2 ml peripheral blood

Results within: 10 business days

Fee: BGN 350

Clinical application

 Cardiovascular diseases 

Coagulation System Disorders

Congenital Thrombophilia

This test analyzes genetic factors related to disorders of the coagulation system and the risk of increased blood clotting, as well as the risk of hypofibrinolysis.

Indications for the test are one or more miscarriages in the family, stillbirth, fetal growth retardation, preeclampsia, preparation for an in vitro procedure, use of hormonal contraceptives, varicose veins, cardiovascular disease in the family.

Number of Markers Tested:: 16

Polymorphisms Included: : Blood coagulation factors: FVL (R506Q), FII 20210G> A, FVII p.R353Q, FXIII p.V34L, FGB c.455G> A Fibrinolysis: PAI 4G / 5G, GPIIIa c.155T> C, TAFI c.505A> G Folate cycle: MTHFR c.77C> T, c.1298A> C, MTRR c.6A> G Other factors: ANXA5, VEGFA c.936C> T, c.-1154G> A, PP13, ACE (I / D)

Research Material: Venous or capillary blood with K2EDTA (purple tube)

Results within: 5-10 business days

Fee: BGN 40 - BGN 330, depending on the prescribed combination of polymorphisms

Diseases and Conditions

Family history of miscarriage ; Stillbirth; Fetal growth retardation; Preeclampsia; Preparation for in vitro procedure; Use of hormonal contraceptives; Varicose veins; Family history of cardiovascular diseases

Download Our Brochure

Pharmacogenetic Tests in Cardiology

Clopidogrel Therapy (Plavix)

Pharmacogenetics in cardiology allows the identification of patients at risk of severe toxicity or those who are likely to benefit from a particular treatment. Thus, it helps to design individualized cancer therapy. 

Diagnostic Range: CYP2C19

Diagnostic Method: Sanger sequencing

Research Material: Venous blood

Results within: 5-10 business days

Fee: BGN 120

Clinical application

Personalized therapy

Pharmacogenetic Tests in Cardiology CYP2C9 VKORC1

Warfarin Therapy (Sintrom)

The Pharmacogenetics in Cardiology allows identification of patients at risk of severe toxicity or those who are likely to benefit from a particular treatment. Thus, it helps to design individualized cancer therapy. There are significant differences between the pharmacogenomics of cancer and other diseases.

Diagnostic Range: CYP2C9, VKORC1

Diagnostic Method: Sanger sequencing/ RFLP

Research Material: Venous blood

Results within: 5-10 business days

Fee: BGN 120

Clinical application

Personalized therapy

Statin Therapy: Simvastatin, Pravastatin, Rosuvastatin

Statin Therapy

The Cardio Pharmacogenetics allows identification of patients at risk of severe toxicity or those who are likely to benefit from a particular treatment. Thus, it helps to design individualized cancer therapy. There are significant differences between the pharmacogenomics of cancer and other diseases.

Diagnostic Range: Statin Therapy: Simvastatin, Pravastatin, Rosuvastatin

Diagnostic Method: Sanger sequencing

Research Material: Venous blood

Results within: 5-10 business days

Fee: BGN 100

Clinical application

Personalized therapy